ES2185185T3 - Nuevos compuestos espiroazabiciclicos heterociclicos. - Google Patents
Nuevos compuestos espiroazabiciclicos heterociclicos.Info
- Publication number
- ES2185185T3 ES2185185T3 ES98934078T ES98934078T ES2185185T3 ES 2185185 T3 ES2185185 T3 ES 2185185T3 ES 98934078 T ES98934078 T ES 98934078T ES 98934078 T ES98934078 T ES 98934078T ES 2185185 T3 ES2185185 T3 ES 2185185T3
- Authority
- ES
- Spain
- Prior art keywords
- sub
- sup
- alkyl
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 229910052717 sulfur Chemical group 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9702746A SE9702746D0 (sv) | 1997-07-18 | 1997-07-18 | New compounds |
| SE9800977A SE9800977D0 (sv) | 1998-03-24 | 1998-03-24 | New compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2185185T3 true ES2185185T3 (es) | 2003-04-16 |
Family
ID=26663041
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98934078T Expired - Lifetime ES2185185T3 (es) | 1997-07-18 | 1998-07-10 | Nuevos compuestos espiroazabiciclicos heterociclicos. |
| ES02005982T Expired - Lifetime ES2231599T3 (es) | 1997-07-18 | 1998-07-10 | Spiro [1-azabicyclo[2.2.2]octane-3,2'(3'h)-furo[2,3-b]pyridine for use in the treatment of psychotic and intellectual impairment disorders. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02005982T Expired - Lifetime ES2231599T3 (es) | 1997-07-18 | 1998-07-10 | Spiro [1-azabicyclo[2.2.2]octane-3,2'(3'h)-furo[2,3-b]pyridine for use in the treatment of psychotic and intellectual impairment disorders. |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US6110914A (enExample) |
| EP (2) | EP1213291B1 (enExample) |
| JP (1) | JP2001510194A (enExample) |
| KR (1) | KR100560036B1 (enExample) |
| CN (1) | CN1117755C (enExample) |
| AR (2) | AR013184A1 (enExample) |
| AT (2) | ATE225792T1 (enExample) |
| AU (1) | AU739022B2 (enExample) |
| BR (1) | BR9810924A (enExample) |
| CA (1) | CA2296031C (enExample) |
| DE (2) | DE69827977T2 (enExample) |
| DK (1) | DK0996622T3 (enExample) |
| EE (1) | EE04399B1 (enExample) |
| ES (2) | ES2185185T3 (enExample) |
| HK (1) | HK1046274B (enExample) |
| HU (1) | HUP0003844A3 (enExample) |
| ID (1) | ID25548A (enExample) |
| IL (2) | IL134086A0 (enExample) |
| IS (2) | IS2027B (enExample) |
| MY (1) | MY116761A (enExample) |
| NO (1) | NO325324B1 (enExample) |
| NZ (1) | NZ502298A (enExample) |
| PL (1) | PL193065B1 (enExample) |
| PT (1) | PT996622E (enExample) |
| RU (1) | RU2202553C2 (enExample) |
| SA (1) | SA98190668B1 (enExample) |
| SI (1) | SI0996622T1 (enExample) |
| SK (1) | SK283484B6 (enExample) |
| TR (1) | TR200000129T2 (enExample) |
| TW (1) | TW515799B (enExample) |
| WO (1) | WO1999003859A1 (enExample) |
Families Citing this family (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU744368B2 (en) | 1997-05-30 | 2002-02-21 | Neurosearch A/S | Spiro-quinuclidine derivatives, their preparation and use |
| US7214686B2 (en) | 1997-06-30 | 2007-05-08 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
| AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| US6277870B1 (en) | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
| SE9900100D0 (sv) * | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
| FR2790474B1 (fr) * | 1999-03-05 | 2001-04-06 | Synthelabo | Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique |
| US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| TWI298068B (en) * | 2000-06-21 | 2008-06-21 | Dainippon Sumitomo Pharma Co | Pharmaceutical composition for schizophrenia |
| US6569865B2 (en) | 2001-06-01 | 2003-05-27 | Astrazeneca Ab | Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine |
| DK1397366T3 (da) * | 2001-06-01 | 2007-05-07 | Astrazeneca Ab | Hidtil ukendt ligander for nicotinacetylcholinreceptorer egnede i terapi |
| WO2003032897A2 (en) * | 2001-10-16 | 2003-04-24 | Astrazeneca Ab | Azabicyclic compounds for the treatment of fibromyalgia syndrome |
| US7067261B2 (en) * | 2001-12-14 | 2006-06-27 | Targacept, Inc. | Methods and compositions for treatment of central nervous system disorders |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| US20030162770A1 (en) | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| KR20040099446A (ko) * | 2002-04-18 | 2004-11-26 | 아스트라제네카 아베 | 헤테로시클릭 화합물 |
| EP1499618B1 (en) * | 2002-04-18 | 2010-10-13 | AstraZeneca AB | Furyl compounds |
| CN1325499C (zh) | 2002-04-18 | 2007-07-11 | 阿斯特拉曾尼卡有限公司 | 噻吩基化合物 |
| ATE375349T1 (de) | 2002-08-02 | 2007-10-15 | Merck & Co Inc | Substituierte furo(2,3-b)pyridin derivate |
| SE0202598D0 (sv) * | 2002-09-02 | 2002-09-02 | Astrazeneca Ab | Alpha-7 Nicotinic receptor agonists and statins in combination |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| EP1581223B2 (en) | 2002-12-06 | 2016-05-25 | The Feinstein Institute for Medical Research | Inhibition of inflamation using alpha 7 receptor-binding cholinergic agonists |
| US7238715B2 (en) * | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
| WO2004063201A1 (ja) * | 2003-01-08 | 2004-07-29 | Mitsubishi Pharma Corporation | 統合失調症治療剤 |
| US20050129610A1 (en) * | 2003-06-24 | 2005-06-16 | Johns Hopkins University | Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor |
| EP1668016A1 (en) * | 2003-09-25 | 2006-06-14 | AstraZeneca AB | Ligands |
| EP1678172B1 (en) | 2003-10-15 | 2009-12-09 | Targacept, Inc. | Azabicyclic compounds for relieving pain and treating central nervous system disorders |
| EP1678183A1 (en) * | 2003-10-21 | 2006-07-12 | AstraZeneca AB | Spirofuropyridine aryl derivatives |
| US20070191815A1 (en) | 2004-09-13 | 2007-08-16 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| AU2005225458B2 (en) | 2004-03-25 | 2008-12-04 | The Feinstein Institutes For Medical Research | Neural tourniquet |
| PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
| ATE489132T1 (de) | 2004-12-27 | 2010-12-15 | The Feinstein Inst Medical Res | Behandlung von entzündlichen erkrankungen durch elektrische stimulation des vagus-nervs |
| CN101248073A (zh) | 2005-08-22 | 2008-08-20 | 塔加西普特公司 | 杂芳基-取代的二氮杂三环烷类、其制备方法及其应用 |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| US8316104B2 (en) | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
| GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| TW200813067A (en) * | 2006-05-17 | 2008-03-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
| US20080242688A1 (en) * | 2007-03-19 | 2008-10-02 | Astrazeneca Ab | Method 741 |
| EP2322168A1 (en) | 2007-04-02 | 2011-05-18 | Parkinson's Institute | Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments |
| WO2009017454A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| WO2009029614A1 (en) | 2007-08-27 | 2009-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
| ATE503754T1 (de) | 2007-10-01 | 2011-04-15 | Comentis Inc | 1h-indol-3-carbonsäure-chinuclidin-4- ylmethylesterderivate als liganden für den nikotinischen alpha-7-acetylcholinrezeptor zur behandlung von alzheimer-krankheit |
| KR20100113163A (ko) | 2008-02-13 | 2010-10-20 | 타가셉트 인코포레이티드 | 알파 ７ 니코틴 작용제 및 항정신병제의 조합 |
| US9211409B2 (en) | 2008-03-31 | 2015-12-15 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of T-cell activity |
| US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
| ES2402084T3 (es) | 2008-06-20 | 2013-04-26 | Astrazeneca Ab | Derivado de dibenzotiazepina y sus usos |
| ES2452484T3 (es) | 2008-11-18 | 2014-04-01 | Setpoint Medical Corporation | Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
| US8788034B2 (en) | 2011-05-09 | 2014-07-22 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| EP2440284B1 (en) | 2009-06-09 | 2018-09-12 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
| US8734798B2 (en) | 2009-10-27 | 2014-05-27 | Ucb Pharma S.A. | Function modifying NAv 1.7 antibodies |
| US9234037B2 (en) | 2009-10-27 | 2016-01-12 | Ucb Biopharma Sprl | Method to generate antibodies to ion channels |
| GB0922435D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | Method |
| GB0922434D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
| US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
| US11051744B2 (en) | 2009-11-17 | 2021-07-06 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
| EP3636314B1 (en) | 2009-12-23 | 2021-09-08 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
| WO2011116282A2 (en) | 2010-03-19 | 2011-09-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nicotinic acetylcholine receptor agonists |
| CN103221411B (zh) | 2010-05-17 | 2016-05-11 | 富瑞姆制药公司 | (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型 |
| US12172017B2 (en) | 2011-05-09 | 2024-12-24 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| RU2455306C1 (ru) * | 2011-05-19 | 2012-07-10 | Государственное образовательное учреждение высшего профессионального образования "Российский университет дружбы народов" (РУДН) | СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 3',4',5,6-ТЕТРАГИДРО-1Н-СПИРО[ПИРИДИН-4,5'-ТИЕНО[2,3-d]ПИРИМИДИНОВ] |
| AU2012276651A1 (en) | 2011-06-30 | 2014-02-06 | Toray Industries, Inc. | Antipruritic agent |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
| CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| ES2694299T3 (es) | 2013-02-07 | 2018-12-19 | Heptares Therapeutics Limited | Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4 |
| US8893339B2 (en) | 2013-03-14 | 2014-11-25 | Select Comfort Corporation | System and method for adjusting settings of a bed with a remote control |
| EA029430B1 (ru) | 2013-06-21 | 2018-03-30 | Такеда Фармасьютикл Компани Лимитед | Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина |
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
| GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
| US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
| US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| TW201617342A (zh) | 2014-07-11 | 2016-05-16 | 阿法馬根公司 | 調節α７活性之啶類 |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 薬剤送達方法及びシステム |
| WO2016126807A1 (en) | 2015-02-03 | 2016-08-11 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| US9724340B2 (en) | 2015-07-31 | 2017-08-08 | Attenua, Inc. | Antitussive compositions and methods |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| CN108882885A (zh) | 2016-01-20 | 2018-11-23 | 赛博恩特医疗器械公司 | 迷走神经刺激的控制 |
| WO2017127758A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| CA3026474A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
| JP2020503950A (ja) | 2017-01-06 | 2020-02-06 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 経皮薬剤送達の装置及び方法 |
| WO2019036470A1 (en) | 2017-08-14 | 2019-02-21 | Setpoint Medical Corporation | TESTING TEST FOR STIMULATION OF NERVE WAVE |
| US11660443B2 (en) | 2018-04-20 | 2023-05-30 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation |
| JP7420797B2 (ja) | 2018-05-29 | 2024-01-23 | モーニングサイド ベンチャー インベストメンツ リミテッド | 薬剤送達の方法及びシステム |
| WO2020064655A1 (en) | 2018-09-24 | 2020-04-02 | Astrazeneca Ab | Azd0328 dosage regime for treating cognitive impairment |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| CA3119992A1 (en) | 2018-11-16 | 2020-05-22 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
| EP3952982B1 (en) | 2019-04-12 | 2024-03-27 | Setpoint Medical Corporation | Vagus nerve stimulation system to treat neurodegenerative disorders |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
| WO2021236977A1 (en) | 2020-05-21 | 2021-11-25 | The Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
| US12444497B2 (en) | 2021-05-17 | 2025-10-14 | Setpoint Medical Corporation | Neurostimulation parameter authentication and expiration system for neurostimulation |
| CN115340736B (zh) * | 2022-05-20 | 2023-09-29 | 扬州实嘉电缆材料有限公司 | 一种氮磷阻燃剂改性聚氯乙烯防火电缆料 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3681363A (en) * | 1970-08-20 | 1972-08-01 | Univ Temple | Spiro(imidazolidine-4,3{40 -quinuclidine)-2,5-diones |
| RU2029796C1 (ru) * | 1992-06-26 | 1995-02-27 | Научно-производственное предприятие "Новатех" | Способ комбинированной ионно-плазменной обработки изделий |
| UA54375C2 (uk) * | 1994-08-24 | 2003-03-17 | Астра Актієболаг | Спіро-азабіциклічні сполуки, способи їх одержання та фармацевтична композиція |
| US5468875A (en) * | 1994-12-22 | 1995-11-21 | American Home Products Corporation | 1-azabicycloheptane derivatives |
| MX9800776A (es) * | 1995-07-28 | 1998-04-30 | Abbott Lab | Furopiridina, tienopiridina, pirrolopiridina y compuestos de triazina, piridazina y pirimidina relacionados utiles para controlar la transmision sinaptica quimica. |
| AR013184A1 (es) | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
-
1998
- 1998-07-06 AR ARP980103280A patent/AR013184A1/es unknown
- 1998-07-10 ES ES98934078T patent/ES2185185T3/es not_active Expired - Lifetime
- 1998-07-10 NZ NZ502298A patent/NZ502298A/en unknown
- 1998-07-10 ES ES02005982T patent/ES2231599T3/es not_active Expired - Lifetime
- 1998-07-10 EP EP02005982A patent/EP1213291B1/en not_active Expired - Lifetime
- 1998-07-10 KR KR1020007000526A patent/KR100560036B1/ko not_active Expired - Fee Related
- 1998-07-10 AU AU83679/98A patent/AU739022B2/en not_active Ceased
- 1998-07-10 HU HU0003844A patent/HUP0003844A3/hu unknown
- 1998-07-10 IL IL13408698A patent/IL134086A0/xx active IP Right Grant
- 1998-07-10 EE EEP200000031A patent/EE04399B1/xx not_active IP Right Cessation
- 1998-07-10 AT AT98934078T patent/ATE225792T1/de not_active IP Right Cessation
- 1998-07-10 AT AT02005982T patent/ATE283859T1/de not_active IP Right Cessation
- 1998-07-10 RU RU2000103958/04A patent/RU2202553C2/ru not_active IP Right Cessation
- 1998-07-10 WO PCT/SE1998/001364 patent/WO1999003859A1/en not_active Ceased
- 1998-07-10 US US09/171,983 patent/US6110914A/en not_active Expired - Lifetime
- 1998-07-10 BR BR9810924-3A patent/BR9810924A/pt not_active Application Discontinuation
- 1998-07-10 ID IDW20000024A patent/ID25548A/id unknown
- 1998-07-10 JP JP2000503083A patent/JP2001510194A/ja active Pending
- 1998-07-10 DE DE69827977T patent/DE69827977T2/de not_active Expired - Fee Related
- 1998-07-10 DK DK98934078T patent/DK0996622T3/da active
- 1998-07-10 SK SK1835-99A patent/SK283484B6/sk not_active IP Right Cessation
- 1998-07-10 TR TR2000/00129T patent/TR200000129T2/xx unknown
- 1998-07-10 PT PT98934078T patent/PT996622E/pt unknown
- 1998-07-10 EP EP98934078A patent/EP0996622B1/en not_active Expired - Lifetime
- 1998-07-10 CN CN98809055A patent/CN1117755C/zh not_active Expired - Fee Related
- 1998-07-10 CA CA002296031A patent/CA2296031C/en not_active Expired - Fee Related
- 1998-07-10 DE DE69808631T patent/DE69808631T2/de not_active Expired - Fee Related
- 1998-07-10 SI SI9830292T patent/SI0996622T1/xx unknown
- 1998-07-10 PL PL338259A patent/PL193065B1/pl not_active IP Right Cessation
- 1998-07-16 MY MYPI98003255A patent/MY116761A/en unknown
- 1998-07-17 TW TW087111679A patent/TW515799B/zh not_active IP Right Cessation
- 1998-10-26 SA SA98190668A patent/SA98190668B1/ar unknown
-
2000
- 2000-01-13 IS IS5338A patent/IS2027B/is unknown
- 2000-01-17 NO NO20000226A patent/NO325324B1/no not_active IP Right Cessation
- 2000-01-17 IL IL134086A patent/IL134086A/en not_active IP Right Cessation
- 2000-06-16 US US09/594,703 patent/US6369224B1/en not_active Expired - Lifetime
-
2002
- 2002-03-08 US US10/093,939 patent/US6703502B2/en not_active Expired - Fee Related
- 2002-10-16 HK HK02107504.2A patent/HK1046274B/en not_active IP Right Cessation
-
2003
- 2003-03-24 US US10/396,215 patent/US6706878B2/en not_active Expired - Fee Related
-
2004
- 2004-03-15 US US10/801,085 patent/US7507744B2/en not_active Expired - Fee Related
-
2005
- 2005-03-16 IS IS7747A patent/IS2434B/is unknown
-
2008
- 2008-03-13 US US12/047,425 patent/US20080153864A1/en not_active Abandoned
- 2008-08-22 AR ARP080103670A patent/AR068013A2/es active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2185185T3 (es) | Nuevos compuestos espiroazabiciclicos heterociclicos. | |
| HUP0004102A2 (hu) | Adenozinszármazékok, eljárás előállításukra, azokat hatóanyagként tartalmazó gyógyszerkészítmények, valamint a hatóanyagok alkalmazása gyógyszerkészítmények előállítására | |
| HU9204032D0 (en) | Method for producing new polycyclic guanine derivatives and pharmaceutical preparatives containing them | |
| FI882081A7 (fi) | 2-substituerade e-fusionerade (1,2,4) triazolo(1,5-c) pyrimidiner, farmaceutiska kompositioner och deras anvaendning. | |
| CO5070570A1 (es) | DERIVADOS DE TIROSINA COMO ACTIVADORES DE hPPAR Y hPPARalfa Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE | |
| MX9705590A (es) | Compuestos heterociclicos sustituidos, procedimiento para su preparacion y composiciones que los contienen. | |
| NO163819C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 1h-imidazo(4,5-c)kinolin og derivater derav. | |
| DK365184A (da) | 1,8-naphthyridinderivater eller estre eller salte deraf, deres fremstilling og anvendelse som farmaceutika | |
| HUP9802865A2 (hu) | N-(szubsztituált fenil-)-pirazol-származékok, előállításuk és alkalmazásuk, a vegyületeket hatóanyagként tartalmazó parazitaellenes készítmények | |
| ES2123652T3 (es) | 7-(2-aminoetil)-benzotiazolonas. | |
| AR009413A1 (es) | Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende | |
| FI915970A0 (fi) | Laekemedel, som aer nyttiga vid vaord av cancer och som har antihistaminegenskaper. | |
| ES2108717T3 (es) | Derivados de la tetrahidropirrolo(1,2-a)pirazina-4-espiro-3'-pirrolidina, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. | |
| AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
| AR012924A1 (es) | Derivados de tiazolidindiona, oxazolidindiona y oxadiazolidindiona, proceso para su preparacion, composiciones y formulaciones farmaceuticas, usode dichos compuestos para la fabricacion de formulaciones y metodo de tratamiento | |
| HRP20070498T3 (en) | Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | |
| ES2155621T3 (es) | Derivados azo del acido 5-aminosalicilico para el tratamiento de la enfermedad inflamatoria intestinal. | |
| DK0861250T3 (da) | Amindin- og isothiourinstofderivater som inhibitorer for nitrogenmonoxidsyntase | |
| AR040140A1 (es) | Derivados de esteres de camptotecina en la posicion 20 | |
| ES2019840A6 (es) | Procedimiento para preparar nuevos derivados de tieno-triazolo-diazepina. | |
| ATE215958T1 (de) | Adenosin-derivate | |
| DK0533827T3 (da) | Oxazolderivater, deres fremstilling og farmaceutiske præparater deraf | |
| AR040139A1 (es) | Camptotecinas con un anillo lactona modificado | |
| MY109517A (en) | Carboxylic acid derivatives | |
| DK0429370T3 (da) | Hiditl ukendte thiophenderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem |